MicroRNA silencing in primates: Towards development of novel therapeutics

Cancer Research

Volumn 69, Issue 2, 2009, Pages 393-395

  Petri, Andreas ^a   Lindow, Morten ^a   Kauppinen, Sakari ^a,b  

^a Santaris Pharma AS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHOXYETHYL MODIFIED OLIGONUCLEOTIDE; 2' O METHYL OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 122 ANTIBODY; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

CANCER THERAPY; CHEMICAL MODIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; MICROARRAY ANALYSIS; NONHUMAN; NORTHERN BLOTTING; POSTTRANSCRIPTIONAL GENE SILENCING; PRIMATE; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PRIMATES;

EID: 58349119585     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2749     Document Type: Review

References (23)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
3. Kloosterman WP, Plasterk RHA. The Diverse Functions of MicroRNAs in Animal Development and Disease. Dev Cell 2006;11:441-50.
4. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
5. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81.
6. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
7. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4.
8. van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316:575-9.
9. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-13.
10. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9.
11. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
12. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
13. Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008;4:77-85.
14. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004;43:13233-41.
15. You Y, Moreira BG, Behlke MA, Owczarzy R. Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res 2006;34:e60.
16. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG. Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet 2007;39:259-63.
17. Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-62.
18. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007;67:11099-101.
19. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
20. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699-708.
21. Gabriely G, Wurdinger T, Kesari S, et al. MiR-21 Promotes Glioma Invasion by Targeting MMP Regulators. Mol Cell Biol 2008;28:5369-80.
22. Crooke ST. Progress in antisense technology: the end of the beginning. Methods Enzymol 2000;313:3-45.
23. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36:4158-71.